# Bio-Rad Laboratories B (BIO.B) — Earnings

BIO.B · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/bio.b/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $2.62 |
| EPS estimate | $1.78 |
| EPS surprise | +47.05% |
| Revenue surprise | +4.19% |
| Revenue | $651.0M |
| Revenue estimate | $624.8M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/12208/000001220826000048/bio-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/1633e870-d343-8249-f914-4355fad9cbc7.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $1.78 | $2.62 | 47.05% | $624.8M | $651.0M |
| Q1 2026 | Apr 30, 2026 | $2.01 | $1.89 | -6.08% | $591.3M | $592.1M |
| Q4 2025 | Feb 12, 2026 | $2.69 | $2.51 | -6.74% | $688.0M | $693.2M |
| Q3 2025 | Oct 29, 2025 | $1.89 | $2.26 | 19.47% | $651.5M | $653.0M |
| Q2 2025 | Jul 31, 2025 | $1.75 | $2.61 | 49.23% | $615.0M | $651.6M |
| Q1 2025 | May 1, 2025 | $1.82 | $2.54 | 39.69% | $573.2M | $585.4M |
| Q4 2024 | Feb 13, 2025 | $2.86 | $2.90 | 1.26% | $679.5M | $667.5M |
| Q3 2024 | Oct 30, 2024 | $1.13 | $2.01 | 78.14% | $626.6M | $649.7M |
| Q2 2024 | Aug 1, 2024 | $2.05 | $3.11 | 51.40% | $643.1M | $638.5M |
| Q1 2024 | May 7, 2024 | $2.17 | $2.29 | 5.36% | $616.6M | $610.8M |
| Q4 2023 | Feb 15, 2024 | $2.84 | $3.10 | 9.23% | $685.1M | $681.2M |
| Q3 2023 | Oct 26, 2023 | $2.76 | $2.33 | -15.72% | $689.5M | $632.1M |
| Q2 2023 | Aug 3, 2023 | $2.64 | $3.00 | 13.82% | $698.0M | $681.1M |
| Q1 2023 | May 4, 2023 | $3.63 | $3.34 | -7.89% | $690.0M | $676.8M |
| Q4 2022 | Feb 16, 2023 | $3.48 | $3.31 | -4.78% | $742.3M | $730.3M |
| Q3 2022 | Oct 27, 2022 | $2.70 | $2.60 | -3.87% | $679.9M | $680.8M |
| Q2 2022 | Jul 28, 2022 | $2.72 | $3.38 | 24.26% | $682.6M | $691.1M |
| Q1 2022 | Apr 28, 2022 | $3.34 | $4.94 | 47.90% | $672.6M | $700.1M |
| Q4 2021 | Feb 10, 2022 | $2.82 | $3.21 | 13.70% | $730.3M | $732.8M |
| Q3 2021 | Oct 28, 2021 | $2.31 | $3.71 | 60.61% | $664.6M | $747.0M |

## Frequently Asked Questions

### When did Bio-Rad Laboratories B (BIO.B) last report earnings?

Bio-Rad Laboratories B last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did BIO.B beat earnings estimates?

Yes. Bio-Rad Laboratories B reported EPS of $2.62 for Q2 2026 against a $1.78 estimate — a 47.05% beat.

### How much revenue did BIO.B report last quarter?

Bio-Rad Laboratories B reported $651.0M in revenue for Q2 2026, against a consensus estimate of $624.8M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).